CXCR4 and lymphoma: These findings are consistent with our recent demonstration of a high uptake for the T22-GFP-H6 nanocarrier in subcutaneous (SC) tumors generated by CXCR4+ lymphoma cells (86.1% of the total ID) and its low or negligible biodistribution to non-DLBCL affected organs (13.9% of the total ID) 15.